These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 2242019)

  • 1. Structure-activity studies with chiral isomers and with segments of the antimitotic marine peptide dolastatin 10.
    Bai RL; Pettit GR; Hamel E
    Biochem Pharmacol; 1990 Oct; 40(8):1859-64. PubMed ID: 2242019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of active isomers, segments, and analogs of dolastatin 10 on ligand interactions with tubulin. Correlation with cytotoxicity.
    Bai R; Roach MC; Jayaram SK; Barkoczy J; Pettit GR; Ludueña RF; Hamel E
    Biochem Pharmacol; 1993 Apr; 45(7):1503-15. PubMed ID: 8471072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.
    Bai R; Friedman SJ; Pettit GR; Hamel E
    Biochem Pharmacol; 1992 Jun; 43(12):2637-45. PubMed ID: 1632820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
    Bai R; Pettit GR; Hamel E
    Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain.
    Bai R; Taylor GF; Cichacz ZA; Herald CL; Kepler JA; Pettit GR; Hamel E
    Biochemistry; 1995 Aug; 34(30):9714-21. PubMed ID: 7626642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antineoplastic agents 337. Synthesis of dolastatin 10 structural modifications.
    Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Durkin KP; Boyd MR; Bai R; Hamel E; Schmidt JM; Chapuis JC
    Anticancer Drug Des; 1995 Oct; 10(7):529-44. PubMed ID: 7495477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.
    Natsume T; Watanabe J; Tamaoki S; Fujio N; Miyasaka K; Kobayashi M
    Jpn J Cancer Res; 2000 Jul; 91(7):737-47. PubMed ID: 10920282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antineoplastic agents 365. Dolastatin 10 SAR probes.
    Pettit GR; Srirangam JK; Barkoczy J; Williams MD; Boyd MR; Hamel E; Pettit RK; Hogan F; Bai R; Chapuis JC; McAllister SC; Schmidt JM
    Anticancer Drug Des; 1998 Jun; 13(4):243-77. PubMed ID: 9627667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15.
    Beckwith M; Urba WJ; Longo DL
    J Natl Cancer Inst; 1993 Mar; 85(6):483-8. PubMed ID: 8445676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
    Bai R; Cichacz ZA; Herald CL; Pettit GR; Hamel E
    Mol Pharmacol; 1993 Oct; 44(4):757-66. PubMed ID: 8232226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity.
    Verdier-Pinard P; Kepler JA; Pettit GR; Hamel E
    Mol Pharmacol; 2000 Jan; 57(1):180-7. PubMed ID: 10617693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
    Aherne GW; Hardcastle A; Valenti M; Bryant A; Rogers P; Pettit GR; Srirangam JK; Kelland LR
    Cancer Chemother Pharmacol; 1996; 38(3):225-32. PubMed ID: 8646796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1.
    Bai R; Durso NA; Sackett DL; Hamel E
    Biochemistry; 1999 Oct; 38(43):14302-10. PubMed ID: 10572005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antineoplastic agents 360. Synthesis and cancer cell growth inhibitory studies of dolastatin 15 structural modifications.
    Pettit GR; Flahive EJ; Boyd MR; Bai R; Hamel E; Pettit RK; Schmidt JM
    Anticancer Drug Des; 1998 Jan; 13(1):47-66. PubMed ID: 9474242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and X-ray crystal structure of the dolabellaauricularia peptide dolastatin 18.
    Pettit GR; Hogan F; Herald DL
    J Org Chem; 2004 Jun; 69(12):4019-22. PubMed ID: 15176826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography.
    Cruz-Monserrate Z; Mullaney JT; Harran PG; Pettit GR; Hamel E
    Eur J Biochem; 2003 Sep; 270(18):3822-8. PubMed ID: 12950266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc.
    Turner T; Jackson WH; Pettit GR; Wells A; Kraft AS
    Prostate; 1998 Feb; 34(3):175-81. PubMed ID: 9492845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of marine toxin dolastatin 10 with porcine brain tubulin: competitive inhibition of rhizoxin and phomopsin A binding.
    Li Y; Kobayashi H; Hashimoto Y; Shirai R; Hirata A; Hayashi K; Hamada Y; Shioiri T; Iwasaki S
    Chem Biol Interact; 1994 Dec; 93(3):175-83. PubMed ID: 7923438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diazonamide A and a synthetic structural analog: disruptive effects on mitosis and cellular microtubules and analysis of their interactions with tubulin.
    Cruz-Monserrate Z; Vervoort HC; Bai R; Newman DJ; Howell SB; Los G; Mullaney JT; Williams MD; Pettit GR; Fenical W; Hamel E
    Mol Pharmacol; 2003 Jun; 63(6):1273-80. PubMed ID: 12761336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tubulin polymerization by vitilevuamide, a bicyclic marine peptide, at a site distinct from colchicine, the vinca alkaloids, and dolastatin 10.
    Edler MC; Fernandez AM; Lassota P; Ireland CM; Barrows LR
    Biochem Pharmacol; 2002 Feb; 63(4):707-15. PubMed ID: 11992639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.